The Comprehensive Genetic Test for Atrial Fibrillation utilizes next-generation sequencing (NGS) to examine 19 genes associated with atrial fibrillation and cardiac conduction disorders. It is a targeted gene panel specifically designed to support accurate diagnosis, risk assessment, and prevention.
More Information
The Comprehensive Genetic Test for Atrial Fibrillation is a targeted genetic test designed to evaluate hereditary forms of atrial fibrillation, a common cardiac arrhythmia affecting the electrical activity of the atria. The comprehensive genetic test for atrial fibrillation includes the analysis of a set of genes, along with selected non-coding variants, enabling a comprehensive assessment of genetic factors associated with inherited susceptibility to atrial fibrillation. It is particularly suitable for individuals with a clinical suspicion of a hereditary form of this condition. Atrial fibrillation is characterized by disorganized atrial electrical activity, leading to irregular and often rapid heart rhythm, which may result in significant clinical complications if left unmanaged.
The comprehensive genetic test for atrial fibrillation includes key genes such as KCNQ1, SCN5A, KCNA5, NPPA, and GJA5, which are involved in ion channel function, cardiac conduction, and electrical signaling within the atria. These genes regulate ion flow and intercellular electrical coupling, which are essential for maintaining coordinated atrial contraction. Disruptions in these pathways result in abnormal atrial excitability and conduction disturbances. The comprehensive genetic test for atrial fibrillation is indicated in individuals presenting with clinical features or family history suggestive of hereditary atrial fibrillation.
The clinical spectrum of atrial fibrillation includes symptoms such as palpitations, dizziness, shortness of breath, chest discomfort, and syncope. The arrhythmia is characterized by an irregular and often rapid heartbeat and may occur intermittently or persistently. In some individuals, the condition may remain asymptomatic, while in others it may lead to significant complications, including an increased risk of stroke and sudden cardiac death. The condition can present at any age, although the risk increases with advancing age. Familial forms may be suspected in cases with early onset and a positive family history, with variability in clinical expression among affected individuals.
The purpose of the comprehensive genetic test for atrial fibrillation is to identify pathogenic variants associated with hereditary atrial fibrillation, supporting accurate diagnosis and differentiation from other arrhythmia disorders. Genetic findings contribute to improved understanding of the molecular mechanisms underlying atrial fibrillation and support appropriate disease classification. The identification of specific genetic alterations assists in risk assessment, prognosis evaluation, and the development of individualized long-term monitoring strategies.
A higher genetic risk is confirmed when pathogenic mutations are found in genes associated with hereditary atrial fibrillation, including KCNQ1, SCN5A, and KCNA5. A lower risk may be inferred when no mutations are detected, though comprehensive clinical follow-up is still essential. The integration of genetic data with clinical findings and electrophysiological evaluation is critical for precise diagnosis, prognosis, and long-term patient care.
The test is performed in a clinical laboratory accredited to ISO 15189 and certified by CLIA and CAP, ensuring the validity, accuracy and international recognition of the results.
